Sold as Ergamisol. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Levamisole Hydrochloride (sold as Ergamisol), first approved Jun 18, 1990, with 0 new uses approved and 0 published complete response letters.
| Dupilumab Therapy in Nephrotic Syndrome in ChildrenNephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent · National University Hospital, Singapore | Phase 2 | Recruiting | Jul 29, 2025 |
| Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)Status Epilepticus · University of Virginia | Phase 3 | Recruiting | Apr 2, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jun 18, 1990 | ErgamisolNDA 20035 · New molecular entity | Janssen Pharma | 12 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
